ClinicalTrials.gg
CompletedNCT04251208MOREUpdated Oct 23, 2026Results posted

MOms in REcovery (MORE) Study: Defining Optimal Care

An observational study in Opioid-Related Disorders, NAS and Substance Use Disorders, sponsored by Trustees of Dartmouth College. Completed at 10 sites in United States. Open to female participants aged 16 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Trustees of Dartmouth College · Observational

How we know

Updated Oct 23, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,510
Ages
16 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.

Enrollment
13th of 122
2,510 · median 85
Started
2019
with 85 others
Observational
122 of 1,223
29 open now
Registered
507th of 1,223
by date

Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 13th largest by enrollment of the 122 observational ones that give a count, is one of 86 that started in 2019, is one of 122 observational ones, and was the 507th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

241 more — sign in →

All 246 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 16 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,223 studies in Opioid-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

Northern New England has among the highest rates of opioid dependence in the U.S. This region also has among the highest rates of opioid-related deaths in the U.S., with a disproportionate high rate among pregnant women with opioid use disorder. Newborns impacted by OUD have increased risk of poor outcomes, including preterm birth and long hospitalization for neonatal withdrawal and other newborn complications. For pregnant women with OUD, medication treatment (MOUD) significantly reduces these risks. Many maternity care providers have begun to prescribe MOUD in their practices. Other practices have maintained the longstanding evidence-based standard of care, referral of patients with OUD to specialty treatment programs. Most pregnant women with OUD have other psychosocial needs, ranging from lack of housing and untreated mental health conditions, to need for parenting education and support. There is variability among practices in terms of types of other services provided to patients. Although pregnancy is a time when women are highly motivated to start MOUD, many women are also likely to discontinue MOUD postpartum due to loss of insurance coverage, difficulty transitioning to another provider, loss of motivation for treatment, or competing demands on time and resources as a new parent.

The challenge for patients, providers, and other stakeholders is to understand the relative advantage of the two MOUD models (receiving MOUD as part of maternity care or at a specialty program) for improving key outcomes for baby \& mother. A second challenge is to understand the relative contributions of onsite services such as mental health care, care coordination and parenting education to improved outcomes. Addressing these challenges is particularly important in rural areas where obstetric practices \& specialty care services are limited. Patients, providers \& other stakeholders need guidance in choosing the optimal models for building programs to provide maternity care for women with OUD.

Read the detailed description

Northern New England has among the highest rates of opioid dependence in the U.S, with prevalence highest and growing among those aged 18-35 years. Regional rates of perinatal opioid use disorders (OUD) reflect this public health crisis; Northern New England region has the highest incidence of opioid-related births in the nation. Perinatal opioid use disorders impact 5-8% of pregnancies in Maine, New Hampshire, and Vermont, three states that have been severely impacted by the current opioid epidemic. Consequences of inadequately treated OUD include premature delivery and other perinatal complications, prolonged newborn hospitalization for neonatal abstinence (NAS), and maternal morbidity and mortality from infectious disease and overdose. In 2013, costs associated with NAS treatment in the U.S. reached $1.5 billion. The epidemic has grown multifold since 2013.

Medication assisted treatment (MAT) with either methadone or buprenorphine is the recommended standard of care during pregnancy. Professionals, including the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics, the Society for Maternal-Fetal Medicine, and the American Society for Addiction Medicine, have called to adopt care models that promote early identification and treatment for pregnant women with OUD. Referral to specialty programs for MAT has been the accepted standard of care, with demonstrated safety for women and their infants. However, in response to the escalating opioid crisis, the ACOG began offering buprenorphine training programs to its members. Consequently, a number of maternity care practices throughout Northern New England now provide integrated MAT services. But even where such integrated programs exist, questions persist on the optimal care model for providing MAT to pregnant women with OUD.

There are patient- and provider- factors associated with variability in effectiveness of what MAT model works best for whom. For women, advantages of buprenorphine over methadone include a lower risk of overdose, fewer drug interactions, the accessibility of office-based treatment delivery in the context of maternity care and demonstrated shorter NAS course. The disadvantages of buprenorphine relative to methadone include potential hepatic dysfunction, lack of long-term data on consequences of fetal exposure for infants, potential limited efficacy in patients with high addiction severity, requirement of moderate withdrawal symptoms prior to initiation to avoid iatrogenic withdrawal, and an increased risk of diversion (i.e., sharing or sale). Despite buprenorphine's demonstrated neonatal advantages, it is not effective for all women. The structure of methadone treatment (daily meeting) may also better align with support needs for some women. For providers, the choice of what medication-assisted approach to offer to patients is often restricted by availability and access to specialty care services.

There is limited literature comparing the effectiveness of integrated versus referral MAT care models for postpartum retention in treatment and women's experiences in these two models. In particular, women with high levels of addiction severity or co-occurring mental health conditions may have prenatal care needs from women with less complex behavioral health concerns. Studies have also not assessed the impact of maternal opioid addiction severity on newborn outcomes and maternal long-term recovery. The best neonatal outcomes will be achieved by providing the most appropriate and effective treatment for mothers.

The challenge for patients, providers, and other stakeholders is determining the optimal approach for delivering MAT during pregnancy and after delivery to improve outcomes. Currently, regional obstetrical practices provide either: (1) Integrated care, in which MAT and associated psychosocial services are delivered on site with obstetrical care, and (2) Referral-based care, in which women receive MAT and obstetrical care in separate, specialized locations. Both models have different potential advantages and disadvantages for mothers with OUD and their babies regarding access, availability, acceptability and quality of MAT, obstetrics and other needed services, and long term follow up and treatment after delivery. While pregnancy motivates women to initiate MAT, relapse to use of opioids and cessation of MAT frequently occur during the first postpartum year, placing both mother and infant at significant risk. Payers and policymakers are also seeking answers about where to invest healthcare resources to increase access to treatment for pregnant women, especially in the current opioid crisis. A disproportionate number of women with OUD are insured through the Medicaid system; Medicaid policy affects women's access to a wide range of services, from reimbursement for same-day services or care coordination, to whether a woman continues to be eligible for benefits after delivery.

Study Aims: The primary aims of this study seek to answer these important patient, provider, and policy questions by comparing the real-world effectiveness of two models of MAT delivery currently in clinical use in Maine, New Hampshire, and Vermont with respect to patient experience of care and perinatal, neonatal, and longer-term substance use treatment outcomes. The following main Comparative Effectiveness Research (CER) Patient-Centered Outcomes Research Institute (PCORI) priority questions will be addressed:

(1) Do clinical and patient-reported outcomes for pregnant and parenting women differ between integrated and referral-based MAT practice models?

To answer this question, the following Primary Specific Aims will be addressed:

Aim 1 (Clinical Outcomes Retrospective). To use clinical record data to evaluate the comparative effectiveness of Integrated and Referral-Based MAT care models on maternal and neonatal outcomes.

Aim 2 (Patient-reported Outcomes Prospective). To use patient reported data to evaluate the comparative effectiveness of Integrated and Referral -Based care models on patient-centered outcomes.

Study Description: This study will collaboratively engage 26 practices providing maternity care across Northern New England, with examples of both integrated care and referral-based models. The study population is pregnant women who receive prenatal care from any of these practices and who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria for an opioid use disorder. A cluster-based observational mixed-methods design will be used to compare outcomes for pregnant women with opioid use disorder receiving prenatal care in obstetric practices that offer MAT through one of two delivery models: Integrated or Referral-based. Retrospective clinical records data (n=2000) from pregnant women with OUD receiving prenatal care at a partner practice will be used to examine Aim 1. Aim 2 will be addressed with a patient-report subsample cohort (n=532) recruited in the 3rd trimester of care and followed to 6 months postpartum via self-report online surveys. The analytic strategy will account for clustering and patient baseline differences to compare outcomes across arms.

03

Conditions studied

  • Opioid-Related Disorders
  • NAS
  • Substance Use Disorders
  • Mental Health

Keywords

  • Pregnancy
  • Infant, Newborn
  • Buprenorphine
  • Methadone
  • Opiate Substitution Treatment
  • Comparative Effectiveness
  • Integrated Care
  • Referral-based Care
  • Postpartum
  • Mental health
04

Who can participate

Ages eligible
16 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Aim 1. Retrospective records from eligible women who delivered in specified time period in one of our 26 partner practices will be reviewed for specified clinical outcomes.

Aim 2. Participants will be recruited from our 26 partner maternity care practices located throughout our northeastern New England region: New Hampshire, Maine, and Vermont.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 16 year and older,
  • Identified opioid use disorder,
  • Receiving prenatal care for current pregnancy at partner practice,
  • Clinic-recorded diagnosis of opioid use disorder,
  • Willing and able to provide .

Exclusion criteria

Exclusion Criteria:

  • Ward of the State
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,510 participants (actual)
Patient registry
No

Groups and cohorts

  • Integrated Care

    This is an observational study and no intervention will be administered. The Integrated Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting that provides medication assisted treatment for opioid use.

    Other: Observational Study

  • Referral-Based Care

    This is an observational study and no intervention will be administered. The Referral-Based Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting and are referred to substance use treatment at a specialty care setting.

    Other: Observational Study

Interventions

  • OtherObservational Study

    No intervention will be administered.

06

What researchers measure

Primary outcomes

  1. Self Report of Medication Treatment for Opioid Use Disorder at 6 Months Postpartum (Yes)

    Portion of participants who self reported receiving MOUD (yes) at 6 months postpartum.

    Time frame: measured 3rd trimester, 3 months postpartum, 6 months postpartum (reported 6 months postpartum)

  2. Number of Participants With High Self Reported Depression Symptoms (Moderate to Severe) From Baseline to 6 Months Postpartum

    * Full unabbreviated scale name: Edinburgh Postnatal Depression Scale * Maximum and minimum scores: 0-30, higher indicates more severe symptoms * Scoring and interpretation of values: Binary variable (0/1) was created based on established cutoffs: \<=14 = 0 low symptoms/\>14=1 moderate to high symptoms

    Time frame: assessed at 3rd trimester, 3 months postpartum and 6 months postpartum (reported 6 months postpartum)

  3. Change in Number of Participants That Self Reported Anxiety: Moderate to Severe From Baseline to 6 Months Postpartum

    * Full unabbreviated scale name: Generalized Anxiety Disorders Scale- 7 * Maximum and minimum scores: 0-21, higher indicates more severe symptoms * Scoring and interpretation of values: 7-item scale with each item scored from 0 (not at all) to 3 (nearly every day), results are summed to calculate overall score. Score \>=10 is considered clinically significant anxiety symptomatology: https://www.mdcalc.com/gad-7-general-anxiety-disorder-7 Binary variables were created for analyses: \< =9 = 0 Low; \>9 = 1 High

    Time frame: Assessed at 3rd trimester, 3 months postpartum and 6 months postpartum (reported 6 months postpartum).

  4. Self Reported Prenatal Care Experience

    Instrument: Experience of Care module of the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician and Groups Survey, 28 items measured on 1-5 Likert, high scores indicative of more positive perceptions. A total score was created by averaging the items on the 5-point response scale, with high scores indicative of more positive patient-centered care perceptions. (range: 1-5).

    Time frame: 3rd Trimester

  5. Medication Treatment for Opioid Use Disorder Yes at Delivery

    Retrospective Cohort: Medical record indication of medication for opioid use disorder as noted in medication list or notes at delivery

    Time frame: Single Point - Delivery

  6. Non-prescribed Opioid Use at Delivery (Yes)

    Retrospective: Indicator of non-prescribed opioid use at delivery as indicated by positive drug screen at delivery or problem notes.

    Time frame: Single Timepoint: Delivery

  7. Perinatal Complications (Yes)

    Indications of perinatal complications as indicated by any of the following in the antenatal period: pre-eclampsia, fetal growth \<10% intrauterine growth restriction. miscarriage, fetal demise, bleeding, placental abruption, deep vein thrombosis

    Time frame: Single Point, at Delivery

Secondary outcomes

  1. Change in Self Reported Physical Quality of Life From 3rd Trimester to 6 Months Postpartum

    Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations.33,34 Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.

    Time frame: Assessed 3rd trimester, 3 months postpartum, 6 months postpartum (6 months postpartum reported)

  2. Change in Self Report Psychological Quality of Life From 3rd Trimester to 6 Months Postpartum

    Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations. Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.

    Time frame: Assessed 3rd trimester, 3 months postpartum, 6 months postpartum (6 months postpartum reported)

  3. Change in Self Reported Social Quality of Life From 3rd Trimester to 6 Months Postpartum

    Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations.33,34 Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.

    Time frame: 3rd trimester, 3 months postpartum, 6 months postpartum (6 months reported)

  4. Self-reported Retention of Child Custody Retention - Yes Responses

    Self-reported Retention of Child Custody (yes/no) at 6 months postpartum

    Time frame: at 6 months postpartum

  5. Self-report Recommended Pediatric Visits Yes at 6 Months

    Self-report Recommended Pediatric Visits at 6 months (Yes)

    Time frame: at 6 months postpartum

  6. Substance Use Other Than Opioid Use at Delivery(Yes)

    Indication of use by positive drug screen at delivery of any of the following at delivery:

    Time frame: Single timepoint, delivery

  7. Neonatal Complications (Yes)

    Indication of any neonatal complications as identified in record by birth weight \<=2500 gm, Apgar\<7 at 5 mins, Apgar \<7 at 10 mins, complications not related to neonatal opioid withdrawal syndrome (NOWS), or other noted medical problems in record.

    Time frame: Single point measured at delivery

  8. Receipt of Treatment for Neonatal Opioid Withdrawal Syndrome After Delivery (Yes)

    Indication of newborn treated with pharmacological agent due to withdrawal symptoms at indicated in record.

    Time frame: single time, within 2 weeks of delivery

07

Results

Posted Oct 23, 2026
Limitations and caveats
This study launched as the COVID pandemic shutdown took place resulting in considerable challenges with recruitment that required passion, creativity and flexibility to expand recruitment strategies in effort to meet recruitment and power goals.

Participant flow

Aim 2. Recruitment occurred July 2019 - May 2023 via flyers and referral. Participants were pregnant persons aged 16 years and older, identified OUD, receiving care in partner setting. Recruitment settings include 68 practices representative of catchment area (28: Integrated/40 Referral). Aim 1. Review of clinical records from eligible women who received prenatal care at partner practices from September 1 2015 - December 31 2022. Records were abstracted from 23/26 partner practices.

Overall Study: Prospective Cohort
Participant flow — Overall Study: Prospective Cohort
MilestoneIntegrated CareReferral-Based Care
Started254186
Completed183150
Not completed7136
Withdrew: Lost to follow-up7136
Overall Study: Retrospective Cohort
Participant flow — Overall Study: Retrospective Cohort
MilestoneIntegrated CareReferral-Based Care
Started9831087
Completed9831087
Not completed00

Outcome measures

PrimarySelf Report of Medication Treatment for Opioid Use Disorder at 6 Months Postpartum (Yes)

Portion of participants who self reported receiving MOUD (yes) at 6 months postpartum.

Time frame:
measured 3rd trimester, 3 months postpartum, 6 months postpartum (reported 6 months postpartum)
Reported as:
Count of participants · Participants
Self Report of Medication Treatment for Opioid Use Disorder at 6 Months Postpartum (Yes)
ParticipantsIntegrated CareReferral-Based Care
Self Report of Medication Treatment for Opioid Use Disorder at 6 Months Postpartum (Yes)122122
Statistical analysis
  • Integrated Care vs Referral-Based Care · generalized estimating equations (GEE) · p = .03 · Odds ratio (or): .73 · 95% CI .55 to .97
PrimaryNumber of Participants With High Self Reported Depression Symptoms (Moderate to Severe) From Baseline to 6 Months Postpartum

* Full unabbreviated scale name: Edinburgh Postnatal Depression Scale * Maximum and minimum scores: 0-30, higher indicates more severe symptoms * Scoring and interpretation of values: Binary variable (0/1) was created based on established cutoffs: \<=14 = 0 low symptoms/\>14=1 moderate to high symptoms

Time frame:
assessed at 3rd trimester, 3 months postpartum and 6 months postpartum (reported 6 months postpartum)
Reported as:
Count of participants · Participants
Number of Participants With High Self Reported Depression Symptoms (Moderate to Severe) From Baseline to 6 Months Postpartum
ParticipantsIntegrated CareReferral-Based Care
Number of Participants With High Self Reported Depression Symptoms (Moderate to Severe) From Baseline to 6 Months Postpartum6558
Statistical analysis
  • Integrated Care vs Referral-Based Care · Mixed Models Analysis · p = .33 · Odds ratio (or): .82 · 95% CI .55 to 1.22Referral condition as referent in General Estimating Equation modeling.
PrimaryChange in Number of Participants That Self Reported Anxiety: Moderate to Severe From Baseline to 6 Months Postpartum

* Full unabbreviated scale name: Generalized Anxiety Disorders Scale- 7 * Maximum and minimum scores: 0-21, higher indicates more severe symptoms * Scoring and interpretation of values: 7-item scale with each item scored from 0 (not at all) to 3 (nearly every day), results are summed to calculate overall score. Score \>=10 is considered clinically significant anxiety symptomatology: https://www.mdcalc.com/gad-7-general-anxiety-disorder-7 Binary variables were created for analyses: \< =9 = 0 Low; \>9 = 1 High

Time frame:
Assessed at 3rd trimester, 3 months postpartum and 6 months postpartum (reported 6 months postpartum).
Reported as:
Count of participants · Participants
Change in Number of Participants That Self Reported Anxiety: Moderate to Severe From Baseline to 6 Months Postpartum
ParticipantsIntegrated CareReferral-Based Care
Change in Number of Participants That Self Reported Anxiety: Moderate to Severe From Baseline to 6 Months Postpartum4941
Statistical analysis
  • Integrated Care vs Referral-Based Care · Mixed Models Analysis · p = .04 · Odds ratio (or): .65 · 95% CI .43 to .97Referral condition as referent
PrimarySelf Reported Prenatal Care Experience

Instrument: Experience of Care module of the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician and Groups Survey, 28 items measured on 1-5 Likert, high scores indicative of more positive perceptions. A total score was created by averaging the items on the 5-point response scale, with high scores indicative of more positive patient-centered care perceptions. (range: 1-5).

Time frame:
3rd Trimester
Reported as:
Mean · score on a scale
Self Reported Prenatal Care Experience
score on a scaleIntegrated CareReferral-Based Care
Self Reported Prenatal Care Experience3.64 ± .573.61 ± .56
Statistical analysis
  • Integrated Care vs Referral-Based Care · Mixed Models Analysis · p = .14 · Mean difference (final values): -.09 · 95% CI -.21 to .03Referral condition as referent
PrimaryMedication Treatment for Opioid Use Disorder Yes at Delivery

Retrospective Cohort: Medical record indication of medication for opioid use disorder as noted in medication list or notes at delivery

Time frame:
Single Point - Delivery
Reported as:
Count of participants · Participants
Medication Treatment for Opioid Use Disorder Yes at Delivery
ParticipantsIntegrated CareReferral-Based Care
Medication Treatment for Opioid Use Disorder Yes at Delivery303291
Statistical analysis
  • Integrated Care vs Referral-Based Care · Odds ratio (or): 1.00 · 95% CI .51 to 1.98
PrimaryNon-prescribed Opioid Use at Delivery (Yes)

Retrospective: Indicator of non-prescribed opioid use at delivery as indicated by positive drug screen at delivery or problem notes.

Time frame:
Single Timepoint: Delivery
Reported as:
Count of participants · Participants
Non-prescribed Opioid Use at Delivery (Yes)
ParticipantsIntegrated CareReferral-Based Care
Non-prescribed Opioid Use at Delivery (Yes)1924
Statistical analysis
  • Integrated Care vs Referral-Based Care · Odds ratio (or): .62 · 95% CI .33 to 1.18
PrimaryPerinatal Complications (Yes)

Indications of perinatal complications as indicated by any of the following in the antenatal period: pre-eclampsia, fetal growth \<10% intrauterine growth restriction. miscarriage, fetal demise, bleeding, placental abruption, deep vein thrombosis

Time frame:
Single Point, at Delivery
Reported as:
Count of participants · Participants
Perinatal Complications (Yes)
ParticipantsIntegrated CareReferral-Based Care
Perinatal Complications (Yes)10786
Statistical analysis
  • Integrated Care vs Referral-Based Care · Odds ratio (or): 1.41 · 95% CI .98 to 2.04
SecondaryChange in Self Reported Physical Quality of Life From 3rd Trimester to 6 Months Postpartum

Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations.33,34 Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.

Time frame:
Assessed 3rd trimester, 3 months postpartum, 6 months postpartum (6 months postpartum reported)
Reported as:
Mean · score on a scale
Change in Self Reported Physical Quality of Life From 3rd Trimester to 6 Months Postpartum
score on a scaleIntegrated CareReferral-Based Care
Change in Self Reported Physical Quality of Life From 3rd Trimester to 6 Months Postpartum67.4 ± 1.5061.6 ± 2.26
Statistical analysis
  • Integrated Care vs Referral-Based Care · Mixed Models Analysis · p = .17 · Mean difference (net): 4.04 · 95% CI -1.74 to 9.80
SecondaryChange in Self Report Psychological Quality of Life From 3rd Trimester to 6 Months Postpartum

Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations. Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.

Time frame:
Assessed 3rd trimester, 3 months postpartum, 6 months postpartum (6 months postpartum reported)
Reported as:
Mean · score on a scale
Change in Self Report Psychological Quality of Life From 3rd Trimester to 6 Months Postpartum
score on a scaleIntegrated CareReferral-Based Care
Change in Self Report Psychological Quality of Life From 3rd Trimester to 6 Months Postpartum59.8 ± 1.4754.3 ± 2.49
Statistical analysis
  • Integrated Care vs Referral-Based Care · Mixed Models Analysis · p = .31 (a priori value set at p\<.05.) · Mean difference (net): 3.35 · 95% CI -3.14 to 9.84Referral Condition as Referent in GEE analyses.
SecondaryChange in Self Reported Social Quality of Life From 3rd Trimester to 6 Months Postpartum

Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations.33,34 Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.

Time frame:
3rd trimester, 3 months postpartum, 6 months postpartum (6 months reported)
Reported as:
Mean · score on a scale
Change in Self Reported Social Quality of Life From 3rd Trimester to 6 Months Postpartum
score on a scaleIntegrated CareReferral-Based Care
Change in Self Reported Social Quality of Life From 3rd Trimester to 6 Months Postpartum60.0 ± 1.5956.6 ± 3.07
Statistical analysis
  • Integrated Care vs Referral-Based Care · Mixed Models Analysis · p = .73 (a priori significance set at p\<.05) · Mean difference (net): 1.18 · 95% CI -5.47 to 7.83Referral condition as referent.
SecondarySelf-reported Retention of Child Custody Retention - Yes Responses

Self-reported Retention of Child Custody (yes/no) at 6 months postpartum

Time frame:
at 6 months postpartum
Reported as:
Count of participants · Participants
Self-reported Retention of Child Custody Retention - Yes Responses
ParticipantsIntegrated CareReferral-Based Care
Self-reported Retention of Child Custody Retention - Yes Responses136121
Statistical analysis
  • Integrated Care vs Referral-Based Care · Mixed Models Analysis · p = .84 · Odds ratio (or): .90 · 95% CI .31 to 2.58
SecondarySelf-report Recommended Pediatric Visits Yes at 6 Months

Self-report Recommended Pediatric Visits at 6 months (Yes)

Time frame:
at 6 months postpartum
Reported as:
Count of participants · Participants
Self-report Recommended Pediatric Visits Yes at 6 Months
ParticipantsIntegrated CareReferral-Based Care
Self-report Recommended Pediatric Visits Yes at 6 Months151134
Statistical analysis
  • Integrated Care vs Referral-Based Care · Mixed Models Analysis · p = .80 · Odds ratio (or): 1.51 · 95% CI .16 to 14.2Referral Condition as referent in logit GEE analyses.
SecondarySubstance Use Other Than Opioid Use at Delivery(Yes)

Indication of use by positive drug screen at delivery of any of the following at delivery:

Time frame:
Single timepoint, delivery
Reported as:
Count of participants · Participants
Substance Use Other Than Opioid Use at Delivery(Yes)
ParticipantsIntegrated CareReferral-Based Care
Substance Use Other Than Opioid Use at Delivery(Yes)7782
Statistical analysis
  • Integrated Care vs Referral-Based Care · Odds ratio (or): .62 · 95% CI .30 to 1.29
SecondaryNeonatal Complications (Yes)

Indication of any neonatal complications as identified in record by birth weight \<=2500 gm, Apgar\<7 at 5 mins, Apgar \<7 at 10 mins, complications not related to neonatal opioid withdrawal syndrome (NOWS), or other noted medical problems in record.

Time frame:
Single point measured at delivery
Reported as:
Count of participants · Participants
Neonatal Complications (Yes)
ParticipantsIntegrated CareReferral-Based Care
Neonatal Complications (Yes)117133
Statistical analysis
  • Integrated Care vs Referral-Based Care · Odds ratio (or): .75 · 95% CI .46 to 1.21
SecondaryReceipt of Treatment for Neonatal Opioid Withdrawal Syndrome After Delivery (Yes)

Indication of newborn treated with pharmacological agent due to withdrawal symptoms at indicated in record.

Time frame:
single time, within 2 weeks of delivery
Reported as:
Count of participants · Participants
Receipt of Treatment for Neonatal Opioid Withdrawal Syndrome After Delivery (Yes)
ParticipantsIntegrated CareReferral-Based Care
Receipt of Treatment for Neonatal Opioid Withdrawal Syndrome After Delivery (Yes)132100
Statistical analysis
  • Integrated Care vs Referral-Based Care · Odds ratio (or): 1.02 · 95% CI .45 to 2.29

Adverse events

Collected over Three years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Integrated Care0/254 (0%)0/254 (0%)0/254 (0%)
Referral-Based Care0/186 (0%)0/186 (0%)0/186 (0%)
Retrospective: Integrated———
Retrospective: Referral———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Integrated CareReferral-Based CareIntegrated Retrospective CohortReferral Retrospective CohortTotal
<=18 years00000
Between 18 and 65 years25418698310872510
>=65 years00000
Age, Continuous
Age, Continuous(years)Integrated CareReferral-Based CareIntegrated Retrospective CohortReferral Retrospective CohortTotal
Mean30.0 ± 5.0430.3 ± 4.7929.0 ± 4.7228.3 ± 4.7230.1 ± 5.00
Sex: Female, Male
Sex: Female, Male(Participants)Integrated CareReferral-Based CareIntegrated Retrospective CohortReferral Retrospective CohortTotal
Female25418698310872510
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Integrated CareReferral-Based CareIntegrated Retrospective CohortReferral Retrospective CohortTotal
Hispanic or Latino34212920104
Not Hispanic or Latino22016593010242339
Unknown or Not Reported00244367
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Integrated CareReferral-Based CareIntegrated Retrospective CohortReferral Retrospective CohortTotal
American Indian or Alaska Native23005
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American1030013
White22817491910372358
More than one race00381048
Unknown or Not Reported146264086
Region of Enrollment
Region of Enrollment(participants)Integrated CareReferral-Based CareIntegrated Retrospective CohortReferral Retrospective CohortTotal
United States25418698310872510
Medication Treatment for OUD
Medication Treatment for OUD(Participants)Integrated CareReferral-Based CareIntegrated Retrospective CohortReferral Retrospective CohortTotal
Count of participants211152——363
Self Report Depression - Moderate to Severe
Self Report Depression - Moderate to Severe(Participants)Integrated CareReferral-Based CareIntegrated Retrospective CohortReferral Retrospective CohortTotal
Count of participants9778——175

4 further baseline measures are reported on the registry.

08

Study locations

10 sites
  • Maine General Hospital
    Augusta, Maine 04330, United States
  • Eastern Maine Medical Center/Northern Light
    Bangor, Maine 04401, United States
  • Dartmouth Hitchcock Keene/Cheshire Medical Center OB-GYN
    Keene, New Hampshire 03431, United States
  • Dartmouth-Hitchcock Medical Center-OB/GYN
    Lebanon, New Hampshire 03756, United States
  • Dartmouth Hitchcock Addiction Treatment, Moms in Recovery
    Lebanon, New Hampshire 03766, United States
  • Dartmouth Hitchcock Bedford/Manchester
    Manchester, New Hampshire 03101, United States
  • Dartmouth Hitchcock Nashua OB-GYN
    Nashua, New Hampshire 03060, United States
  • Southwestern Vermont Medical Center OB-GYN
    Bennington, Vermont 05201, United States
  • Central Vermont Medical Center
    Berlin Corners, Vermont 05602, United States
  • Brattleboro Memorial Hospital OB-GYN
    Brattleboro, Vermont 05301, United States
09

References and documents

Publications

  • Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD. Incidence of Neonatal Abstinence Syndrome - 28 States, 1999-2013. MMWR Morb Mortal Wkly Rep. 2016 Aug 12;65(31):799-802. doi: 10.15585/mmwr.mm6531a2. PubMed 27513154 ↗
  • Patrick SW, Schiff DM; COMMITTEE ON SUBSTANCE USE AND PREVENTION. A Public Health Response to Opioid Use in Pregnancy. Pediatrics. 2017 Mar;139(3):e20164070. doi: 10.1542/peds.2016-4070. Epub 2017 Feb 20. PubMed 28219965 ↗
  • Jones HE. Treating opioid use disorders during pregnancy: historical, current, and future directions. Subst Abus. 2013;34(2):89-91. doi: 10.1080/08897077.2012.752779. PubMed 23577898 ↗
  • Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010 Dec 9;363(24):2320-31. doi: 10.1056/NEJMoa1005359. PubMed 21142534 ↗
  • Reddy UM, Davis JM, Ren Z, Greene MF; Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes Workshop Invited Speakers. Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. Obstet Gynecol. 2017 Jul;130(1):10-28. doi: 10.1097/AOG.0000000000002054. PubMed 28594753 ↗
  • Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health. 2015 Aug;105(8):e55-63. doi: 10.2105/AJPH.2015.302664. Epub 2015 Jun 11. PubMed 26066931 ↗
  • Milligan K, Niccols A, Sword W, Thabane L, Henderson J, Smith A, Liu J. Maternal substance use and integrated treatment programs for women with substance abuse issues and their children: a meta-analysis. Subst Abuse Treat Prev Policy. 2010 Sep 1;5:21. doi: 10.1186/1747-597X-5-21. PubMed 20809957 ↗
  • Wilder C, Lewis D, Winhusen T. Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder. Drug Alcohol Depend. 2015 Apr 1;149:225-31. doi: 10.1016/j.drugalcdep.2015.02.012. Epub 2015 Feb 19. PubMed 25735465 ↗
  • Flavin J. (2002) A Glass Half Full? Harm reduction amongpregnant women who use cocaine. Journal of Drug Issues, 32(3):973-998. https://journals.sagepub.com/doi/10.1177/002204260203200315
  • Roberts SC, Nuru-Jeter A. Women's perspectives on screening for alcohol and drug use in prenatal care. Womens Health Issues. 2010 May-Jun;20(3):193-200. doi: 10.1016/j.whi.2010.02.003. PubMed 20457407 ↗
  • Wright TE, Schuetter R, Fombonne E, Stephenson J, Haning WF 3rd. Implementation and evaluation of a harm-reduction model for clinical care of substance using pregnant women. Harm Reduct J. 2012 Jan 19;9:5. doi: 10.1186/1477-7517-9-5. PubMed 22260315 ↗
  • Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, Coyle MG, Selby P, Stine SM, Fischer G. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012 Nov;107 Suppl 1(0 1):5-27. doi: 10.1111/j.1360-0443.2012.04035.x. PubMed 23106923 ↗
  • Roberts SC, Pies C. Complex calculations: how drug use during pregnancy becomes a barrier to prenatal care. Matern Child Health J. 2011 Apr;15(3):333-41. doi: 10.1007/s10995-010-0594-7. PubMed 20232126 ↗
  • Terplan M, Kennedy-Hendricks A, Chisolm MS. Prenatal Substance Use: Exploring Assumptions of Maternal Unfitness. Subst Abuse. 2015 Sep 20;9(Suppl 2):1-4. doi: 10.4137/SART.S23328. eCollection 2015. PubMed 26448685 ↗
  • Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014 Feb 1;65(2):158-70. doi: 10.1176/appi.ps.201300256. PubMed 24247147 ↗
  • Saloner B, Karthikeyan S. Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004-2013. JAMA. 2015 Oct 13;314(14):1515-7. doi: 10.1001/jama.2015.10345. No abstract available. PubMed 26462001 ↗
  • Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O'Connor PG, Schottenfeld RS. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008 Mar-Apr;17(2):116-20. doi: 10.1080/10550490701860971. PubMed 18393054 ↗
  • Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, Grusing S, Devine B, Chou R. Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review. Ann Intern Med. 2017 Feb 21;166(4):268-278. doi: 10.7326/M16-2149. Epub 2016 Dec 6. PubMed 27919103 ↗
  • Boyd SC, Marcellus L. (2007) With child: substance use during pregnancy, a woman-centered approach. Halifax [N.S.]: Fernwood Pub.
  • Hall JL, van Teijlingen ER. A qualitative study of an integrated maternity, drugs and social care service for drug-using women. BMC Pregnancy Childbirth. 2006 Jun 13;6:19. doi: 10.1186/1471-2393-6-19. PubMed 16772022 ↗
  • Lefebvre L, Midmer D, Boyd JA, Ordean A, Graves L, Kahan M, Pantea L. Participant perception of an integrated program for substance abuse in pregnancy. J Obstet Gynecol Neonatal Nurs. 2010 Jan-Feb;39(1):46-52. doi: 10.1111/j.1552-6909.2009.01083.x. PubMed 20409102 ↗
  • Corse SJ, McHugh MK, Gordon SM. Enhancing provider effectiveness in treating pregnant women with addictions. J Subst Abuse Treat. 1995 Jan-Feb;12(1):3-12. PubMed 7752295 ↗
  • Armstrong MA, Gonzales Osejo V, Lieberman L, Carpenter DM, Pantoja PM, Escobar GJ. Perinatal substance abuse intervention in obstetric clinics decreases adverse neonatal outcomes. J Perinatol. 2003 Jan;23(1):3-9. doi: 10.1038/sj.jp.7210847. PubMed 12556919 ↗
  • Goler NC, Armstrong MA, Taillac CJ, Osejo VM. Substance abuse treatment linked with prenatal visits improves perinatal outcomes: a new standard. J Perinatol. 2008 Sep;28(9):597-603. doi: 10.1038/jp.2008.70. Epub 2008 Jun 26. PubMed 18580882 ↗
  • Meyer M, Phillips J. Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas. Prev Med. 2015 Nov;80:18-22. doi: 10.1016/j.ypmed.2015.07.015. Epub 2015 Jul 26. PubMed 26212632 ↗
  • Ordean A, Kahan M, Graves L, Abrahams R, Boyajian T. Integrated care for pregnant women on methadone maintenance treatment: Canadian primary care cohort study. Can Fam Physician. 2013 Oct;59(10):e462-9. PubMed 24130301 ↗
  • Jansson LM, Velez ML. Infants of drug-dependent mothers. Pediatr Rev. 2011 Jan;32(1):5-12; quiz 12-3. doi: 10.1542/pir.32-1-5. No abstract available. PubMed 21196501 ↗
  • Terplan M, Ramanadhan S, Locke A, Longinaker N, Lui S. Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions. Cochrane Database Syst Rev. 2015 Apr 2;2015(4):CD006037. doi: 10.1002/14651858.CD006037.pub3. PubMed 25835053 ↗
  • Morgenstern J, Blanchard KA, McCrady BS, McVeigh KH, Morgan TJ, Pandina RJ. Effectiveness of intensive case management for substance-dependent women receiving temporary assistance for needy families. Am J Public Health. 2006 Nov;96(11):2016-23. doi: 10.2105/AJPH.2005.076380. Epub 2006 Oct 3. PubMed 17018819 ↗
  • Dowdell JA, Fenwick J, Bartu A, Sharp J. Midwives' descriptions of the postnatal experiences of women who use illicit substances: a descriptive study. Midwifery. 2009 Jun;25(3):295-306. doi: 10.1016/j.midw.2007.03.008. Epub 2007 Jul 5. PubMed 17614166 ↗
  • Tuten M, Jones HE. A partner's drug-using status impacts women's drug treatment outcome. Drug Alcohol Depend. 2003 Jun 5;70(3):327-30. doi: 10.1016/s0376-8716(03)00030-9. PubMed 12757970 ↗
  • Niccols A, Milligan K, Sword W, Thabane L, Henderson J, Smith A. Integrated programs for mothers with substance abuse issues: A systematic review of studies reporting on parenting outcomes. Harm Reduct J. 2012 Mar 19;9:14. doi: 10.1186/1477-7517-9-14. PubMed 22429792 ↗
  • Niccols A, Milligan K, Smith A, Sword W, Thabane L, Henderson J. Integrated programs for mothers with substance abuse issues and their children: a systematic review of studies reporting on child outcomes. Child Abuse Negl. 2012 Apr;36(4):308-22. doi: 10.1016/j.chiabu.2011.10.007. Epub 2012 Apr 5. PubMed 22483158 ↗
  • Back SE, Lawson KM, Singleton LM, Brady KT. Characteristics and correlates of men and women with prescription opioid dependence. Addict Behav. 2011 Aug;36(8):829-34. doi: 10.1016/j.addbeh.2011.03.013. Epub 2011 Mar 25. PubMed 21514061 ↗
  • Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, Hillhouse M, Brady KT, Ling W. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse. 2011 Sep;37(5):313-23. doi: 10.3109/00952990.2011.596982. PubMed 21854273 ↗
  • Najavits LM, Weiss RD, Shaw SR. The link between substance abuse and posttraumatic stress disorder in women. A research review. Am J Addict. 1997 Fall;6(4):273-83. PubMed 9398925 ↗
  • Chander G, McCaul ME. Co-occurring psychiatric disorders in women with addictions. Obstet Gynecol Clin North Am. 2003 Sep;30(3):469-81. doi: 10.1016/s0889-8545(03)00079-2. PubMed 14664322 ↗
  • Dube SR, Felitti VJ, Dong M, Chapman DP, Giles WH, Anda RF. Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse childhood experiences study. Pediatrics. 2003 Mar;111(3):564-72. doi: 10.1542/peds.111.3.564. PubMed 12612237 ↗
  • Heffner JL, Blom TJ, Anthenelli RM. Gender differences in trauma history and symptoms as predictors of relapse to alcohol and drug use. Am J Addict. 2011 Jul-Aug;20(4):307-11. doi: 10.1111/j.1521-0391.2011.00141.x. Epub 2011 May 31. PubMed 21679261 ↗
  • Seng JS, D'Andrea W, Ford JD. Complex Mental Health Sequelae of Psychological Trauma Among Women in Prenatal Care. Psychol Trauma. 2014 Jan;6(1):41-49. doi: 10.1037/a0031467. PubMed 25558308 ↗
  • Simpson TL, Miller WR. Concomitance between childhood sexual and physical abuse and substance use problems. A review. Clin Psychol Rev. 2002 Feb;22(1):27-77. doi: 10.1016/s0272-7358(00)00088-x. PubMed 11793578 ↗
  • Benningfield MM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Fischer G, Jones HE, Martin PR. Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict. 2010 Sep-Oct;19(5):416-21. doi: 10.1111/j.1521-0391.2010.00064.x. PubMed 20716304 ↗
  • Jones HE, Svikis D, Rosado J, Tuten M, Kulstad JL. What if they do not want treatment?: lessons learned from intervention studies of non-treatment-seeking, drug-using pregnant women. Am J Addict. 2004 Jul-Sep;13(4):342-57. doi: 10.1080/10550490490483008. PubMed 15370933 ↗
  • Thompson MP, Kingree JB. The frequency and impact of violent trauma among pregnant substance abusers. Addict Behav. 1998 Mar-Apr;23(2):257-62. doi: 10.1016/s0306-4603(97)00032-4. PubMed 9573429 ↗
  • Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat. 2007 Jan;32(1):19-25. doi: 10.1016/j.jsat.2006.06.015. Epub 2006 Oct 13. PubMed 17175395 ↗
  • Tuten M, Heil SH, O'Grady KE, Fitzsimons H, Chisolm MS, Jones HE. The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients. Am J Drug Alcohol Abuse. 2009;35(5):358-63. doi: 10.1080/00952990903108231. PubMed 20180664 ↗
  • Benningfield MM, Dietrich MS, Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Fischer G, Martin PR. Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes. Addiction. 2012 Nov;107 Suppl 1(0 1):74-82. doi: 10.1111/j.1360-0443.2012.04041.x. PubMed 23106929 ↗
  • Ashley OS, Marsden ME, Brady TM. Effectiveness of substance abuse treatment programming for women: a review. Am J Drug Alcohol Abuse. 2003;29(1):19-53. doi: 10.1081/ada-120018838. PubMed 12731680 ↗
  • Flavin J, Paltrow LM. Punishing pregnant drug-using women: defying law, medicine, and common sense. J Addict Dis. 2010 Apr;29(2):231-44. doi: 10.1080/10550881003684830. PubMed 20407979 ↗
  • Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder--and its treatment. JAMA. 2014 Apr 9;311(14):1393-4. doi: 10.1001/jama.2014.2147. No abstract available. PubMed 24577059 ↗
  • Schroedel JR, Fiber P. Punitive versus public health oriented responses to drug use by pregnant women. Yale J Health Policy Law Ethics. 2001 Spring;1:217-35. No abstract available. PubMed 12669331 ↗
  • Jansson LM, Svikis D, Lee J, Paluzzi P, Rutigliano P, Hackerman F. Pregnancy and addiction. A comprehensive care model. J Subst Abuse Treat. 1996 Jul-Aug;13(4):321-9. doi: 10.1016/s0740-5472(96)00070-0. PubMed 9076650 ↗
  • Shaw MR, Lederhos C, Haberman M, Howell D, Fleming S, Roll J. Nurses' Perceptions of Caring for Childbearing Women who Misuse Opioids. MCN Am J Matern Child Nurs. 2016 Jan-Feb;41(1):37-42. doi: 10.1097/NMC.0000000000000208. PubMed 26658534 ↗
  • Friedrichs A, Spies M, Harter M, Buchholz A. Patient Preferences and Shared Decision Making in the Treatment of Substance Use Disorders: A Systematic Review of the Literature. PLoS One. 2016 Jan 5;11(1):e0145817. doi: 10.1371/journal.pone.0145817. eCollection 2016. PubMed 26731679 ↗
  • Brener L, Resnick I, Ellard J, Treloar C, Bryant J. Exploring the role of consumer participation in drug treatment. Drug Alcohol Depend. 2009 Nov 1;105(1-2):172-5. doi: 10.1016/j.drugalcdep.2009.06.016. Epub 2009 Jul 21. PubMed 19625143 ↗
  • Simpatico TA. Vermont responds to its opioid crisis. Prev Med. 2015 Nov;80:10-1. doi: 10.1016/j.ypmed.2015.04.002. Epub 2015 Apr 11. PubMed 25869219 ↗
  • Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012 May 9;307(18):1934-40. doi: 10.1001/jama.2012.3951. Epub 2012 Apr 30. PubMed 22546608 ↗
  • Jumah NA. Rural, Pregnant, and Opioid Dependent: A Systematic Review. Subst Abuse. 2016 Jun 20;10(Suppl 1):35-41. doi: 10.4137/SART.S34547. eCollection 2016. PubMed 27375357 ↗
  • Oetzel JG, Zhou C, Duran B, Pearson C, Magarati M, Lucero J, Wallerstein N, Villegas M. Establishing the psychometric properties of constructs in a community-based participatory research conceptual model. Am J Health Promot. 2015 May-Jun;29(5):e188-202. doi: 10.4278/ajhp.130731-QUAN-398. Epub 2014 Apr 10. PubMed 24720389 ↗
  • Oetzel JG, Villegas M, Zenone H, White Hat ER, Wallerstein N, Duran B. Enhancing stewardship of community-engaged research through governance. Am J Public Health. 2015 Jun;105(6):1161-7. doi: 10.2105/AJPH.2014.302457. Epub 2015 Apr 16. PubMed 25880952 ↗
  • Wallerstein NB, Duran B. Using community-based participatory research to address health disparities. Health Promot Pract. 2006 Jul;7(3):312-23. doi: 10.1177/1524839906289376. Epub 2006 Jun 7. PubMed 16760238 ↗
  • Sandoval JA, Lucero J, Oetzel J, Avila M, Belone L, Mau M, Pearson C, Tafoya G, Duran B, Iglesias Rios L, Wallerstein N. Process and outcome constructs for evaluating community-based participatory research projects: a matrix of existing measures. Health Educ Res. 2012 Aug;27(4):680-90. doi: 10.1093/her/cyr087. Epub 2011 Sep 21. PubMed 21940460 ↗
  • Damschroder LJ, Hagedorn HJ. A guiding framework and approach for implementation research in substance use disorders treatment. Psychol Addict Behav. 2011 Jun;25(2):194-205. doi: 10.1037/a0022284. PubMed 21443291 ↗
  • Hesselink G, Johnson J, Batalden P, Carlson M, Geense W, Groenewoud S, Jones S, Roy B, Sansone C, Wolf JRLM, Bart B, Wollersheim H. 'Reframing Healthcare Services through the Lens of Co-Production' (RheLaunCh): a study protocol for a mixed methods evaluation of mechanisms by which healthcare and social services impact the health and well-being of patients with COPD and CHF in the USA and The Netherlands. BMJ Open. 2017 Sep 7;7(9):e017292. doi: 10.1136/bmjopen-2017-017292. PubMed 28882923 ↗
  • Portela MC, Pronovost PJ, Woodcock T, Carter P, Dixon-Woods M. How to study improvement interventions: a brief overview of possible study types. BMJ Qual Saf. 2015 May;24(5):325-36. doi: 10.1136/bmjqs-2014-003620. Epub 2015 Mar 25. PubMed 25810415 ↗
  • Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000 Sep;11(5):550-60. doi: 10.1097/00001648-200009000-00011. PubMed 10955408 ↗
  • Westfall PH, Tobias RD, Wolfinger RD. Multiple comparisons and multiple tests using SAS. Cary, N.C.: SAS Pub.; 2011
  • Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50. doi: 10.1186/1748-5908-4-50. PubMed 19664226 ↗
  • Stuart EA, Marcus SM, Horvitz-Lennon MV, Gibbons RD, Normand SL. Using Non-experimental Data to Estimate Treatment Effects. Psychiatr Ann. 2009 Jul 1;39(7):41451. doi: 10.3928/00485713-20090625-07. PubMed 20563313 ↗
  • Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011 May;46(3):399-424. doi: 10.1080/00273171.2011.568786. Epub 2011 Jun 8. PubMed 21818162 ↗
  • Lee J, Little TD. A practical guide to propensity score analysis for applied clinical research. Behav Res Ther. 2017 Nov;98:76-90. doi: 10.1016/j.brat.2017.01.005. Epub 2017 Jan 19. PubMed 28153337 ↗
  • Hedeker DR, Gibbons RD. Wiley Series in Probability and Statistics: Longitudinal Data Analysis. 2006. ISBN-13: 978-0471420279
  • Molenberghs G, Kenward MG. Missing Data in Clinical Studies. Chichester: Wiley; 2007. ISBN: 978-0-470-84981-1
  • Varadhan R, Segal JB, Boyd CM, Wu AW, Weiss CO. A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. J Clin Epidemiol. 2013 Aug;66(8):818-25. doi: 10.1016/j.jclinepi.2013.02.009. Epub 2013 May 4. PubMed 23651763 ↗
  • Lagakos SW. The challenge of subgroup analyses--reporting without distorting. N Engl J Med. 2006 Apr 20;354(16):1667-9. doi: 10.1056/NEJMp068070. No abstract available. PubMed 16625007 ↗
  • Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005 Nov;15(9):1277-88. doi: 10.1177/1049732305276687. PubMed 16204405 ↗
  • Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol. 2015 Aug;35(8):650-5. doi: 10.1038/jp.2015.36. Epub 2015 Apr 30. PubMed 25927272 ↗
  • Killip S, Mahfoud Z, Pearce K. What is an intracluster correlation coefficient? Crucial concepts for primary care researchers. Ann Fam Med. 2004 May-Jun;2(3):204-8. doi: 10.1370/afm.141. PubMed 15209195 ↗
  • McHugo GJ, Drake RE, Whitley R, Bond GR, Campbell K, Rapp CA, Goldman HH, Lutz WJ, Finnerty MT. Fidelity outcomes in the National Implementing Evidence-Based Practices Project. Psychiatr Serv. 2007 Oct;58(10):1279-84. doi: 10.1176/ps.2007.58.10.1279. PubMed 17914003 ↗
  • Patrick SW, Dudley J, Martin PR, Harrell FE, Warren MD, Hartmann KE, Ely EW, Grijalva CG, Cooper WO. Prescription opioid epidemic and infant outcomes. Pediatrics. 2015 May;135(5):842-50. doi: 10.1542/peds.2014-3299. Epub 2015 Apr 13. PubMed 25869370 ↗
  • Ordean A, Kahan M, Graves L, Abrahams R, Kim T. Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a canadian multisite cohort study. J Obstet Gynaecol Can. 2015 Mar;37(3):252-257. doi: 10.1016/S1701-2163(15)30311-X. PubMed 26001872 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jan 2024, 54 months.

Results were first posted in Oct 2026, 2 years 8 months after primary completion.

Of 74 non-industry observational studies under Opioid-Related Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 54 months is above that.

Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2018
First posted
Jan 31, 2020
StartActual
Jul 30, 2019
Primary completionActual
Jan 31, 2024
CompletionActual
Jan 31, 2024
Results first posted
Oct 23, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 23, 2026
Sites
1 site added, 1 site removed
Show site
  • Central Vermont Medical Center · Berlin Corners, United States
Show 1 removed
  • Central Vermont Medical Center · Berlin, United States
Oct 23, 2026
Enrollment
444→2510
Oct 23, 2026
Eligibility
Revised
Oct 23, 2026
Primary outcomes
1 edited, 6 added, 6 removed
What changed in the outcomes
  • EditedSelf report (Y/N)Report of medication assisted treatment (MAT)Medication Treatment for opioid use disorderOpioid Use Disorder at 6 Months Postpartum (Yes)Time frame: Comparison of results at three time points: between 28-36 weeks of pregnancy (third trimester); 3 months after delivery, and 6 months after delivery. → measured 3rd trimester, 3 months postpartum, 6 months postpartum (reported 6 months postpartum)
  • AddedNumber of Participants With High Self Reported Depression Symptoms (Moderate to Severe) From Baseline to 6 Months PostpartumTime frame: assessed at 3rd trimester, 3 months postpartum and 6 months postpartum (reported 6 months postpartum)
  • AddedChange in Number of Participants That Self Reported Anxiety: Moderate to Severe From Baseline to 6 Months PostpartumTime frame: Assessed at 3rd trimester, 3 months postpartum and 6 months postpartum (reported 6 months postpartum).
  • AddedSelf Reported Prenatal Care ExperienceTime frame: 3rd Trimester
  • AddedMedication Treatment for Opioid Use Disorder Yes at DeliveryTime frame: Single Point - Delivery
  • AddedNon-prescribed Opioid Use at Delivery (Yes)Time frame: Single Timepoint: Delivery
  • AddedPerinatal Complications (Yes)Time frame: Single Point, at Delivery
  • RemovedUrine opioid toxicology laboratory report, included in maternal clinical recordTime frame: Comparison of results at three time points: between 28-36 weeks of pregnancy (third trimester); 36-41 weeks of pregnancy (delivery episode); and at the last documented outpatient postpartum visit (occurring 2-6 weeks after delivery).
  • RemovedPresence or absence of MAT medication in medication list, outpatient narrative, or hospital admission notes included in clinical record.Time frame: Comparison of results at three time points: between 28-36 weeks of pregnancy (third trimester); 36-41 weeks of pregnancy (delivery episode); and at the last documented outpatient postpartum visit (occurring 2-6 weeks after delivery).
  • RemovedPresence or absence of pre-specified perinatal complications in problem list, narrative notes, admission notes in clinical record (Present/Not present).Time frame: at time of delivery
  • RemovedSelf report on Edinburgh Postnatal Depression Scale (EPDS) (scale)Time frame: Comparison of numeric scores at three time points: between 28-36 weeks of pregnancy (third trimester); 3 months after delivery, and 6 months after delivery.
  • RemovedSelf report on Generalized Anxiety Disorders Scale (GAD-7) (scale)Time frame: Comparison of numeric scores at three time points: between 28-36 weeks of pregnancy (third trimester); 3 months after delivery, and 6 months after delivery.
  • RemovedSelf report on Post-traumatic Stress Disorder Checklist for Civilians (PCL-C)Time frame: Comparison of numeric scores at three time points: between 28-36 weeks of pregnancy (third trimester); 3 months after delivery, and 6 months after delivery.
Oct 23, 2026
Documents
Secondary outcomes
8 added, 7 removed
What changed in the outcomes
  • AddedChange in Self Reported Physical Quality of Life From 3rd Trimester to 6 Months PostpartumTime frame: Assessed 3rd trimester, 3 months postpartum, 6 months postpartum (6 months postpartum reported)
  • AddedChange in Self Report Psychological Quality of Life From 3rd Trimester to 6 Months PostpartumTime frame: Assessed 3rd trimester, 3 months postpartum, 6 months postpartum (6 months postpartum reported)
  • AddedChange in Self Reported Social Quality of Life From 3rd Trimester to 6 Months PostpartumTime frame: 3rd trimester, 3 months postpartum, 6 months postpartum (6 months reported)
  • AddedSelf-reported Retention of Child Custody Retention - Yes ResponsesTime frame: at 6 months postpartum
  • AddedSelf-report Recommended Pediatric Visits Yes at 6 MonthsTime frame: at 6 months postpartum
  • AddedSubstance Use Other Than Opioid Use at Delivery(Yes)Time frame: Single timepoint, delivery
  • AddedNeonatal Complications (Yes)Time frame: Single point measured at delivery
  • AddedReceipt of Treatment for Neonatal Opioid Withdrawal Syndrome After Delivery (Yes)Time frame: single time, within 2 weeks of delivery
  • RemovedUrine drug/alcohol toxicology laboratory or point of care testing report, included in maternal clinical recordTime frame: Comparison of results at three time points: between 28-36 weeks of pregnancy (third trimester); 36-41 weeks of pregnancy (delivery episode); and at the last documented outpatient postpartum visit (occurring 2-6 weeks after delivery).
  • Removed(Present/Not present). Reference to presence or absence of pre-specified neonatal complications in narrative notes, admission notes in clinical record.Time frame: at time of delivery
  • RemovedReference to presence or absence of pre-specified neonatal complications in outpatient narrative notes in clinical record (Present/Not present).Time frame: at maternal postpartum outpatient visit
  • RemovedReference to use of pharmacologic agent to treat neonatal opioid withdrawal in maternal hospital discharge summary or narrative notes (present/absent)Time frame: At delivery hospitalization
  • RemovedReference to use of pharmacologic agent to treat neonatal opioid withdrawal in maternal hospital discharge summary or narrative notes (present/absent)Time frame: At maternal outpatient postpartum visit
  • RemovedChange in Child Custody Status: Self report (Y/N)Time frame: compared across two time periods: in the third trimester (between 28-36 weeks of pregnancy); and at 3 and 6 months postpartum
  • RemovedParticipants recruited through partner maternity care practices and by snowball sampling throughout New Hampshire, Maine, and Vermont.Time frame: in the third trimester (between 28-36 weeks of pregnancy)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Central Vermont Medical Center · Berlin Corners, United States
    Show 1 removed
    • Central Vermont Medical Center · Berlin, United States
    Enrollment 444→2510
    Eligibility Revised
    Primary outcomes 1 edited, 6 added, 6 removed
    What changed in the outcomes
    • EditedSelf report (Y/N)Report of medication assisted treatment (MAT)Medication Treatment for opioid use disorderOpioid Use Disorder at 6 Months Postpartum (Yes)Time frame: Comparison of results at three time points: between 28-36 weeks of pregnancy (third trimester); 3 months after delivery, and 6 months after delivery. → measured 3rd trimester, 3 months postpartum, 6 months postpartum (reported 6 months postpartum)
    • AddedNumber of Participants With High Self Reported Depression Symptoms (Moderate to Severe) From Baseline to 6 Months PostpartumTime frame: assessed at 3rd trimester, 3 months postpartum and 6 months postpartum (reported 6 months postpartum)
    • AddedChange in Number of Participants That Self Reported Anxiety: Moderate to Severe From Baseline to 6 Months PostpartumTime frame: Assessed at 3rd trimester, 3 months postpartum and 6 months postpartum (reported 6 months postpartum).
    • AddedSelf Reported Prenatal Care ExperienceTime frame: 3rd Trimester
    • AddedMedication Treatment for Opioid Use Disorder Yes at DeliveryTime frame: Single Point - Delivery
    • AddedNon-prescribed Opioid Use at Delivery (Yes)Time frame: Single Timepoint: Delivery
    • AddedPerinatal Complications (Yes)Time frame: Single Point, at Delivery
    • RemovedUrine opioid toxicology laboratory report, included in maternal clinical recordTime frame: Comparison of results at three time points: between 28-36 weeks of pregnancy (third trimester); 36-41 weeks of pregnancy (delivery episode); and at the last documented outpatient postpartum visit (occurring 2-6 weeks after delivery).
    • RemovedPresence or absence of MAT medication in medication list, outpatient narrative, or hospital admission notes included in clinical record.Time frame: Comparison of results at three time points: between 28-36 weeks of pregnancy (third trimester); 36-41 weeks of pregnancy (delivery episode); and at the last documented outpatient postpartum visit (occurring 2-6 weeks after delivery).
    • RemovedPresence or absence of pre-specified perinatal complications in problem list, narrative notes, admission notes in clinical record (Present/Not present).Time frame: at time of delivery
    • RemovedSelf report on Edinburgh Postnatal Depression Scale (EPDS) (scale)Time frame: Comparison of numeric scores at three time points: between 28-36 weeks of pregnancy (third trimester); 3 months after delivery, and 6 months after delivery.
    • RemovedSelf report on Generalized Anxiety Disorders Scale (GAD-7) (scale)Time frame: Comparison of numeric scores at three time points: between 28-36 weeks of pregnancy (third trimester); 3 months after delivery, and 6 months after delivery.
    • RemovedSelf report on Post-traumatic Stress Disorder Checklist for Civilians (PCL-C)Time frame: Comparison of numeric scores at three time points: between 28-36 weeks of pregnancy (third trimester); 3 months after delivery, and 6 months after delivery.
    Secondary outcomes 8 added, 7 removed
    What changed in the outcomes
    • AddedChange in Self Reported Physical Quality of Life From 3rd Trimester to 6 Months PostpartumTime frame: Assessed 3rd trimester, 3 months postpartum, 6 months postpartum (6 months postpartum reported)
    • AddedChange in Self Report Psychological Quality of Life From 3rd Trimester to 6 Months PostpartumTime frame: Assessed 3rd trimester, 3 months postpartum, 6 months postpartum (6 months postpartum reported)
    • AddedChange in Self Reported Social Quality of Life From 3rd Trimester to 6 Months PostpartumTime frame: 3rd trimester, 3 months postpartum, 6 months postpartum (6 months reported)
    • AddedSelf-reported Retention of Child Custody Retention - Yes ResponsesTime frame: at 6 months postpartum
    • AddedSelf-report Recommended Pediatric Visits Yes at 6 MonthsTime frame: at 6 months postpartum
    • AddedSubstance Use Other Than Opioid Use at Delivery(Yes)Time frame: Single timepoint, delivery
    • AddedNeonatal Complications (Yes)Time frame: Single point measured at delivery
    • AddedReceipt of Treatment for Neonatal Opioid Withdrawal Syndrome After Delivery (Yes)Time frame: single time, within 2 weeks of delivery
    • RemovedUrine drug/alcohol toxicology laboratory or point of care testing report, included in maternal clinical recordTime frame: Comparison of results at three time points: between 28-36 weeks of pregnancy (third trimester); 36-41 weeks of pregnancy (delivery episode); and at the last documented outpatient postpartum visit (occurring 2-6 weeks after delivery).
    • Removed(Present/Not present). Reference to presence or absence of pre-specified neonatal complications in narrative notes, admission notes in clinical record.Time frame: at time of delivery
    • RemovedReference to presence or absence of pre-specified neonatal complications in outpatient narrative notes in clinical record (Present/Not present).Time frame: at maternal postpartum outpatient visit
    • RemovedReference to use of pharmacologic agent to treat neonatal opioid withdrawal in maternal hospital discharge summary or narrative notes (present/absent)Time frame: At delivery hospitalization
    • RemovedReference to use of pharmacologic agent to treat neonatal opioid withdrawal in maternal hospital discharge summary or narrative notes (present/absent)Time frame: At maternal outpatient postpartum visit
    • RemovedChange in Child Custody Status: Self report (Y/N)Time frame: compared across two time periods: in the third trimester (between 28-36 weeks of pregnancy); and at 3 and 6 months postpartum
    • RemovedParticipants recruited through partner maternity care practices and by snowball sampling throughout New Hampshire, Maine, and Vermont.Time frame: in the third trimester (between 28-36 weeks of pregnancy)
    + 5 other changes: verification date, description, conditions, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04251208
Lead sponsor
Trustees of Dartmouth College
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Sarah E. Lord (Associate Professor of Psychiatry, Biomedical Data Science and Pediatrics; Director, Dissemination and Implementation Core, Center for Technology and Behavioral Health, Trustees of Dartmouth College) — Principal investigator
First posted
Jan 31, 2020
Start date
Jul 30, 2019
Primary completion
Jan 31, 2024
Completion
Jan 31, 2024
Results posted
Oct 23, 2026
Last update
Oct 23, 2026

Study contacts

Sarah E Lord, PhD
principal investigator · Dartmouth College
Daisy Goodman, DNP, MPH
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion